Timothy Eugene Sullivan is CFO at Apellis Pharmaceuticals, Inc. (APLS). They have made 12 open-market trades across 1 company since 2019, most recently 2026-05-14.
CIK 0001707000
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $695K since 2019, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 41,250 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2026-01-22 | 2026-01-23 | $21.77 | $224K | +7.2% | +4.1% | +89.6% |
| APLS | SELL | 2026-01-20 | 2026-01-21 | $19.79 | $57K | +9.0% | +6.3% | +95.4% |
| APLS | SELL | 2026-01-13 | 2026-01-15 | $22.19 | $86K | +12.4% | +5.1% | +99.0% |
| APLS | SELL · 10b5-1 | 2025-10-21 | 2025-10-23 | $28.03 | $280K | -28.5% | -29.6% | -26.8% |
| APLS | SELL · 10b5-1 | 2025-09-08 | 2025-09-10 | $27.86 | $2.1M | -9.9% | -3.6% | -8.7% |
| APLS | SELL | 2025-01-29 | 2025-01-30 | $29.52 | $16K | -5.8% | -20.6% | -36.6% |
| APLS | SELL | 2025-01-22 | 2025-01-23 | $30.43 | $188K | -6.4% | -10.8% | -43.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $104K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-13 | 2025-01-14 | $28.70 | $62K | +5.2% | -3.1% | -31.8% |
| APLS | SELL · 10b5-1 | 2024-04-01 | 2024-04-02 | $58.66 | $235K | -6.5% | -14.3% | -34.5% |
| APLS | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $63.22 | $379K | -8.5% | -9.6% | -35.3% |
| APLS | SELL | 2024-02-12 | 2024-02-13 | $67.77 | $194K | +7.0% | -15.8% | -35.8% |
| APLS | SELL | 2024-01-29 | 2024-01-31 | $64.14 | $116K | +6.8% | +0.7% | -30.4% |
| APLS | SELL | 2024-01-22 | 2024-01-23 | $65.00 | $231K | -6.3% | +1.3% | -28.6% |
| APLS | SELL | 2024-01-16 | 2024-01-17 | $66.81 | $299K | -1.8% | +3.3% | -22.2% |
| APLS | SELL · 10b5-1 | 2023-11-30 | 2023-12-01 | $54.73 | $1.5M | +5.1% | +2.4% | +3.6% |
| APLS | SELL · 10b5-1 | 2023-07-03 | 2023-07-06 | $89.95 | $1.2M | -54.0% | -72.8% | -56.7% |
| APLS | SELL · 10b5-1 | 2023-06-05 | 2023-06-06 | $88.78 | $12.2M | -1.4% | -3.7% | -52.4% |
| APLS | BUY | 2019-08-29 | 2019-09-03 | $29.71 | $695K | -4.3% | -15.1% | -4.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.